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Abstract 
 
Sporadic Alzheimer’s disease (sAD) is the most common form of dementia. Rats injected 
intracerebroventricularly with streptozotocin (STZ-icv) develop insulin-resistant brain state 
and represent a non-transgenic sAD model with a number of AD-like cognitive and 
neurochemical features. We explored cognitive, structural and ultrastructural changes in the 
brain of the STZ-icv rat model over a course of nine months. 
Cognitive functions were measured in the STZ-icv- (0.3, 1 and 3 mg/kg) and age-matched 
control rats by Passive avoidance test. Structural changes were assessed by Nissl and 
Bielschowsky silver staining. Immunohistochemistry and electron microscopy analysis were 
used to detect amyloid β- (Aβ1-42) and hyperphosphorylated tau (AT8) accumulation and 
ultrastructural changes in the brain.  
Memory decline was time- (≤3 months/acute, ≥3 months/progressive) and STZ-icv dose-
dependent. Morphological changes were manifested as thinning of parietal cortex (≥1 month) 
and corpus callosum (9 months), and were more pronounced in the 3 mg/kg STZ group. 
Early neurofibrillary changes (AT8) were detected from 1 month onward in the neocortex, 
and progressed after 3 months to the hippocampus. Intracellular Aβ1-42 accumulation was 
found in the neocortex at 3 months following STZ-icv treatment, while diffuse Aβ1-42-positive 
plaque-like formations were found after 6 months in the neocortex and hippocampus. 
Ultrastructural changes revealed enlargement of Golgi apparatus, pyknotic nuclei, and time-
dependent increase in lysosome size, number, and density.  
Our data provide a staging of cognitive, structural/ultrastructural, and neuropathological 
markers in the STZ-icv rat model that in many aspects seems to be generally comparable to 
stages seen in human sAD. 
 
Keywords: Alzheimer’s disease, streptozotocin, amyloid protein, tau protein, lysosomes, 
cognitive decline 
 
3 
 
Introduction 
 
Alzheimer’s disease (AD) is the most common form of dementia, clinically characterized by a 
progressive memory loss. The major neuropathological hallmarks of AD are senile (amyloid) 
plaques and neurofibrillary tangles (NFTs) that demonstrate regionally specific distribution in 
cerebral cortex and in certain subcortical nuclei (Braak and Braak 1991, 1995; Selkoe 2001; 
Thal et al. 2002b). Amyloid β1-42 (Aβ1-42) is the main component of senile plaques, which may 
occur as diffuse plaques, intermingled amongst neuronal processes that appear to remain 
unaffected by this process, and compact or cored plaques that damage brain tissue. The 
latter induce microglia and astrocyte activation, and are typically surrounded by dystrophic, 
tau-containing neurites. Hyperphosporylated tau protein is the main component of NFTs, 
which are located in the cytoplasm of neuronal cell bodies and neuritic processes (Buee et 
al. 2000; Hinrichs et al. 2012; Simic et al. 1998).  
 
   Contrary to the rare and inherited early-onset form of AD, the cause of the prevailing, 
sporadic late-onset AD form (sAD) is unknown. In addition to the various mechanisms of 
neural degeneration, like mitochondrial dysfunction (Diana et al. 2008) and oxidative stress 
(Leuner et al. 2012; Simic et al. 2009; Thome et al. 1997; Völkel et al. 2006), or 
environmental factors (Shaw and Höglinger 2008) suggested to play a role in the 
etiopathogenesis of sAD, evidence supports the concept of brain insulin resistance and 
metabolic dysfunction being important mediators of pathophysiological changes in sAD 
(Correia et al. 2011; De Felice et al. 2014; de la Monte and Tong 2014; Hoyer 2004; 
Salkovic-Petrisic et al. 2009). Modelling of brain insulin resistance is therefore relevant in this 
respect but has not been sufficiently studied. The identification of disease-causing mutations 
in proteins such as Aβ precursor protein (APP) and presenilins 1 and 2 (PS1, PS2) as well as 
pathogenic mutations in tau protein, resulted in development of many transgenic mice AD 
models (Lithner et al. 2011). However, such models are representative for rare familial AD 
forms and their reliability as models for sAD has been recently questioned as well as their 
actual use in AD drug discovery (Bales 2012; Zach and Ashe 2010). Amyloid-related gene 
manipulation in transgenic mice AD models is inevitable starting point as antecendent to Aβ 
pathology as well as to brain insulin dysfunction whose development differs between the 
transgenic mice AD models (Chen et al. 2013; Niwa et al. 2002; Pedersen et al. 2006; 
Pedrós et al. 2014). For this reason trangenic mice AD models are inappropriate for 
exploring the cause, onset and development of the pathological Aβ deposition in the brain in 
a condition that is not associated with mutations of the APP/PS1 genes and in which brain 
insulin dysfunction might precede Aβ pathology (like in sAD).  
 
   A different approach that does not involve genetic engineering has been used to generate 
a non-transgenic rat model of insulin resistance in the brain by intracerebroventricular (icv) 
injection of streptozotocin (STZ-icv model) (Lanner and Hoyer 1998). STZ (2-deoxy-2-(3-
(methyl-3-nitrosoureido)-D-glucopyranose)) is a cytotoxic compound that acts selectively on 
insulin producing/secreting cells and causes type 1 diabetes mellitus in adult rats following 
parenteral administration at high doses (Szkudelski 2001). Multiple parenteral treatments 
with low-to-moderate STZ doses cause insulin resistance and type 2 diabetes mellitus by 
affecting insulin receptor (IR) signalling (Blondel and Portha 1989; Giorgino et al. 1992; 
Kadowaki et al. 1984). Icv administration of low STZ doses does not induce a systemic 
diabetic condition in rats, but has been convincingly shown to induce insulin-resistant brain 
state characterized by altered tyrosine kinase activity of IR and dysfunctional signalling 
downstream the IR signaling pathways (Agrawal et al. 2010, 2011; Grünblatt et al. 2007; 
Lester-Coll et al. 2006; Osmanovic-Barilar et al. 2014; Salkovic-Petrisic et al. 2006; Steen et 
al. 2005), accompanied by a decrease in brain glucose and energy metabolism (Hoyer and 
Lannert 2007; Lannert and Hoyer 1998; Nitsch and Hoyer 1991; Plaschke and Hoyer 1993). 
Additionally, the STZ-icv rat model has been demonstrated to develop remarkable behavioral 
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and neuropathological AD-like features, in particular cognitive (Mayer et al. 1990) and brain 
cholinergic deficits (Hellweg et al. 1992), as well as oxidative stress (Correia et al. 2013; 
Sharma and Gupta 2001), neuroinflammation, and astrogliosis (Chen et al. 2013; Javed et al. 
2011; Kraska et al. 2012; Prickaerts et al. 1999, 2000; Rodrigues et al. 2010; Shoham et al. 
2003, 2007). Severely affected STZ-icv rats also demonstrate extensive cell loss, inferred 
from increase in the volume of the ventricular system (Kraska et al. 2012; Prickaerts et al. 
2000; Shoham et al. 2003), and a significant enlargement of the trans-Golgi compartment in 
cortical neurons at the ultrastructural level (Grieb et al. 2004). In addition, increased Aβ1-42 
and hyperphosphorylated tau immunoreactivity have been detected in the hippocampus of 
STZ-icv rats and mice (Chen et al. 2013; Correia et al. 2013; Deng et al. 2009; Kosaraju et 
al. 2013; Shingo et al. 2012). Accumulation of Aβ in the cerebral microvasculature (cerebral 
amyloid angiopathy, CAA) has been observed first in the meningeal capillaries (Salkovic-
Petrisic et al. 2006), progressing subsequently to the intracortical blood vessels of STZ-icv 
rats (Salkovic-Petrisic et al. 2011).  
 
   With the exception of a long-term follow-up of CAA development (Salkovic-Petrisic et al. 
2013) and dysfunction in IR signaling cascade (Osmanovic-Barilar et al. 2014), there have 
been no reports on neurochemical or neuropathological changes in the brain or of cognitive 
deficits in STZ-icv models investigated in periods of more than 6 months after STZ injection. 
To characterize and validate the model better, in this 9-month follow-up study, we have 
assessed the onset, development, and progression of Aβ1-42 and hyperphosphorylated tau 
immunopositive lesions, ultrastructural changes in the brain, as well as cognitive deficits in 
the STZ-icv rats as a function of STZ dose and post-treatment time. 
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Materials and Methods 
 
Chemicals 
Streptozotocin was purchased from Sigma-Aldrich Chemie (Munich, Germany). Phospho-
PHF-tau pSer202/Thr205 monoclonal antibody (AT8, cat. no. MN1020) was purchased from 
Thermo Scientific (Waltham, MA, USA). Monoclonal antibodies against amyloid β1-42 were 
purchased from Signet, (Signet Laboratories, Inc., Dedham, MA, USA, 2006, cat. No. 39142) 
and from Covance (Princeton, NJ, USA; clone 12F4, cat. No. 39142 and cat. No. 39136). 
Vectastain Elite ABC Kit (Cat. No. PK-6200) while normal goat serum (S-1000), biotinylated 
goat anti-mouse IgG antibody (cat. no. BA-9200) and ImmPACT AEC peroxidase substrate 
(cat. no. SK-4205) were purchased from Vector Laboratories (Burlingame, CA, USA). 
Paraformaldehyde was purchased from Sigma Aldrich (cat. no. 16005, St. Louis, MO, USA). 
MultiLink–HRP kit was purchased from Biogenex (cat. no. LP000-UL, San Ramon, CA, USA) 
and Romulin AEC chromogen was purchased from Biocarta (cat. no. RAEC810L, San Diego, 
CA, USA). 
 
Animals 
Three-month-old male Wistar rats weighing 280-350 g (Department of Pharmacology, 
University of Zagreb School of Medicine) were used in all experiments. The rats were kept 2-
3 per cage in a room with a 12 h light/12 h dark cycle (lights on 07:00 – 19:00 h), and the 
room temperature and humidity set in the range of 21-25°C and 40-70% respectively. All 
animals were kept on standardized food pellets and water ad libitum.  
 
Surgery 
Rats were subjected to deep general anesthesia (chloral hydrate 300 mg/kg, ip, Merck, 
Darmstadt, Germany), followed by icv injection of STZ (0.3, 1 or 3 mg/kg, dissolved in 0.05 M 
citrate buffer, pH 4.5, bilaterally 2 µl/ventricle split in two doses given on day 1 and 3), 
according to the procedure first described by Noble et al. (1967) and used elsewhere 
(Grünblatt et al. 2007; Lackovic and Salkovic 1990; Osmanovic-Barilar et al. 2014; Salkovic-
Petrisic et al. 2011; Salkovic et al. 1995). Control animals were given an equal volume of 
vehicle icv by the same procedure on day 1 and 3.  
 
Experimental design 
STZ-icv (0.3, 1, or 3 mg/kg) and respective age-matched control (treated icv with 0.05 M 
citrate buffer, pH 4.5) animals were sacrificed in after 1 week, and 1, 3, 6, or 9 months 
following the treatment, respectively. Cognitive testing was performed immediately before 
sacrifice at each time-point (N = 8-10 per group, four groups per experiment: control, STZ 0.3 
mg/kg, STZ 1 mg/kg, STZ 3 mg/kg). In additional set of experiments rats treated with high (3 
mg/kg) STZ-icv dose and age-matched controls were sacrificed 2 weeks, and 1, 3, 6 and 9 
months after the treatment (two groups per experiment: control, STZ 3 mg/kg). Animals were 
euthanised in deep anaesthesia (thiopental:diazepam 50 mg/kg:6 mg/kg intraperitoneally) 
followed by decapitation in all experiments.  
 
Cognitive testing  
Memory functions were tested by passive avoidance test with a step-through type passive 
avoidance task (Ugo Basile, Comerio, Italy) utilizing the natural preference of rats for dark 
environments. It is a fear-motivated avoidance task in which rats learn to refrain from 
stepping through a door to an apparently safer but previously punishment-related dark 
compartment. The latency to refrain from crossing into the punishing compartment serves as 
an index of the ability to avoid, and allows memory assessment. Those rats that had no 
alterations in memory functions (vehicle-treated controls) had to remember that a foot shock 
would follow entering the dark compartment (therefore had to stay longer in the lit 
compartment on the test day). In case of impaired memory functions, rats would not 
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associate the foot shock with the dark environment and spend less time in the lit 
compartment. Passive avoidance test performance lasts for three days starting with a 
habituation day to make the rat familiar with the environment (without foot shock, or pre-
shock latency), followed by a training day in which foot shock (0.3-0.5 mA, depending on the 
rat weight, duration 2 s) is delivered; and finally a testing day (without foot shock). Time 
required for entrance of a rat in the dark compartment was measured with a cut-off time of 5 
min. In all of the experiments, passive avoidance test was performed only once per 
group/experiment. 
 
Tissue preparation   
Animals were deeply anesthetized with chloral hydrate (300 mg/kg ip) or thiopental:diazepam 
(50 mg/kg:6 mg/kg ip) and perfused with saline followed by 4% paraformaldehyde, pH 7.4  in 
a standard procedure. Brains were quickly removed and embedded in paraffin, then cut on a 
sliding microtome into 8 µm-thick sections. Tissue sections were mounted on slides and 
dried by leaving the slide at room temperature overnight. Tissue sections for Aβ 
immunohistochemistry were obtained from animals in experiments (3 mg STZ-icv only) 
different from those used for cognitive testing and structural tau protein and electron 
microscopy analysis. 
 
Immunohistochemistry 
The slides were first deparaffinized and rehydrated. Before immunohistochemical staining 
with AT8 and monoclonal antibodies against Aβ1-42, slides were subjected to antigen retrieval 
step (1 h in 80% formic acid for Aβ1-42 immunostaining, and 30 min on 95°C in sodium citrate 
buffer, pH 6.0) and then washed and incubated in 0.7% H2O2 for 15 min. Slides were then 
washed in TBS (pH 7.6) and blocked with 10% normal goat serum for 1 h and incubated with 
primary antibodies AT8 (1:100) and Aβ1-42 (1:2,000) diluted in TBS with 1% BSA overnight at 
4°C. Next day slides (incubated with AT8) were washed and incubated with biotinylated 
secondary goat anti-mouse antibody for 1 h, followed by incubation with Vectastain ABC kit 
for 30 min. Immunoreaction was developed by incubation with ABC peroxidase substrate kit 
for 4 min. Slides were counterstained with haematoxylin for 1 min, washed with H2O and 
mounted. Slides incubated with Aβ1-42 were incubated with MultiLink kit following the 
manufacturer’s protocol. The reaction was developed by incubation with Romulin AEC 
chromogen for 4 min. Slides were then counterstained with haematoxylin, washed, 
dehydrated, and mounted. Specific positive Aβ1-42 signal in the rat brain was obtained by 
antibody purchased from Signet (Dedham, MA, USA). Immunohistochemistry was performed 
on four sections per brain (number of animals per group: 1-2 for Aβ1-42 and 3-4 for AT8). 
Human AD brain tissue samples were used as a positive control in both AT8 and Aβ1-42 
immunohistochemistry. 
 
Bielschowsky silver staining 
Slides were deparaffinized and rehydrated, and then incubated for 20 min in the dark with a 
20% AgNO3 solution. Slides were then washed with dH2O and incubated for another 15 min 
with the same solution but with added ammonium, and washed in dH2O with ammonium. 
Then slides were incubated for 3-5 min or until they darken in the AgNO3/ammonium solution 
with developer (20 ml of formalin, a drop of concentrated HNO3, 0.5 g of citric acid, and 100 
ml of dH2O) and then washed and fixated in 5% sodium thiosulfate for 5 min (Uchihara 
2007). Slides were then washed, dehydrated, and mounted.  
 
Nissl staining  
Slides were deparaffinised and rehydrated and after that the slides were stained in 0.5% 
cresyl violet solution diluted with dH2O (ratio 1:4) until it darkens. Slides were then washed 
with dH2O and differentiated in 70% ethyl alcohol with 2-3 drops of 10% acetic acid. After 
differentiation slides were dehydrated in 70% ethyl alcohol, followed by 96% and 100% ethyl 
alcohol and cleared in xylene and mounted with permanent mounting medium. 
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Electron microscopy 
The animals were anesthetized and transcardially perfused using 6% glutaraldehyde in 0.1 M 
phosphate buffer. The isolated tissue samples of hippocampus and neocortex (1 STZ-icv 
animal treated with 3 mg/kg dose and 1 age-matched control group) were further fixed by 
immersion for 24 h. After postfixation in 1% OsO4 and dehydration, the tissue was embedded 
in Durcupan from Fluka-Sigma Aldrich (St. Louis, MO, USA). Semithin (1 µm) and ultrathin 
sections (70 nm) were cut on a PowerTome XL Ultramicrotome (RMC Products). Semithin 
sections were stained with toluidine blue and examined by light microcopy. Ultrathin sections 
were contrasted with 2% uranyl acetate and with Reynolds lead citrate solution and 
examined by transmission electron microscope TEM 902A (Zeiss). 
 
Ethics 
Animal procedures, carried out at the University of Zagreb Medical School (Zagreb, Croatia), 
were in compliance with current institutional, national (The Animal Protection Act, 
NN135/2006; NN 47/2011), and international (Directive 2010/63/EU) guidelines governing 
the use of experimental animals. The experiments were approved by the national regulatory 
body responsible for issuing ethical approval, Croatian Ministry of Agriculture (licence No. 
UP/I-322-01/11-01/100 to MSP for the research approved by Croatian Ministry of Science, 
Education and Sport, project 108-1080003-0020), and Ethical Committee, Medical School of 
Zagreb (licence 380-59/11-500-77/26).  
 
Statistics 
The significance of between-group differences in the passive avoidance test (mean ± SD) 
was tested by Kruskall-Wallis one-way analysis of variance (ANOVA) followed by Mann-
Whitney U-test, with significance set at α = 0.05. Quantitative analysis of the signal captured 
by Bielschowsky silver and Nissl staining (N = 4 per group, 2 sections per brain) was done by 
cellSense Dimension software and further statistical analysis (mean ± SD) was done by 
Kruskal-Wallis and Mann-Whitney U test (p < 0.05). 
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Results 
Cognitive deficits 
 
Compared to the age-matched controls, STZ-icv rats demonstrated severe cognitive deficits 
manifested as lower post-shock latency time in the passive avoidance test observed from 1 
to 9 months (Fig. 1). Lower latency time in STZ-icv rats indicated diminished capacity to 
remember that entering into the dark compartment would result in being subjected to an 
electric shock. Memory impairment in STZ-icv rats was clearly dose-dependent and most 
pronounced with the highest STZ-icv dose used (up to -95% compared to controls, p < 0.05; 
Fig. 1). Additionally, cognitive deficits were time-dependent, showing a specific time pattern 
of changes with all 3 doses; pronounced acute cognitive decline 1 month after STZ treatment 
(phase I), partial or complete improvement of memory impairment at month 3 (phase II), 
followed by  a slow chronic cognitive decline persisiting up to 9 months after the STZ-icv 
treatment (phase III), which was sustained and progressive at medium and high STZ doses 
(p < 0.05; Fig. 1). Although such a time-pattern of cognitive deficits was evident with all three 
doses, only the lowest (0.03 mg/kg) STZ dose regime was associated with full reversibility of 
acute cognitive decline (latency time not different from the control group after 3 months), and 
partial reversibility of chronic cognitive decline (cognitive deficit persisted but was much lower 
in comparison to medium- and high-dose regimes, p < 0.05) at month 9 (Fig. 1). Analysis of 
individual latency time (data not shown) revealed subgroups within each STZ-icv group: 
subgroup 1 with latency time close to controls (298 s) and subgroup 2 with values 
substantially lower than controls (40-50 s). While the ratio of animals between subgroups 1 
and 2 was ≤2 vs ≥9 in each STZ-icv treated-group at month 1, indicating a severe acute 
response regardless of the dose, dose-dependent reduction in subgroup 1, and increment in 
subgroup 2 at month 3 (7 vs 3, 5 vs 5 and 2 vs 8 in 0.3, 1, and 3 mg/kg group, respectively) 
indicated that early pathology is fully compensated in some animals but not in others of the 
same dose-group. 
 
Morphological changes  
 
Nissl and Bielschowsky silver staining showed that morphologic changes after STZ-icv 
treatment are dose-dependent (more pronounced with a high dose) and that the cerebral 
cortex is affected earlier than the corpus callosum (Figs 2, 3). Bielschowsky silver staining 
demonstrated fiber loss in corpus callosum with high (-31%, p < 0.05) and medium (-10%, p 
< 0.05) STZ-icv dose 9 months after the treatment but did not reveal any silver-stained 
plaques or NFTs at any of the time-points regardless of the dose (Fig. 2). Nissl staining also 
showed dose-dependent pathological changes in the brain of STZ-icv treated rats particularly 
as a reduction of cortical thickness (Fig. 3). The thickness of the parietal cortex dropped in 
STZ-icv treated rats 1 month after treatment with medium (-5%, p < 0.05) and high (-11%, p 
< 0.05) doses compared to age-matched controls, and in high-dose compared to low-dose 
STZ-icv rats (-11%, p < 0.05; Fig. 3). Although mild, the effect was stable thereafter and 
present in medium- and high-dose compared to low-dose STZ-icv treated rats (-7% both 
doses, p < 0.05) after 6 months and in high-dose STZ-icv treated rat compared to all other 
groups (-11%, p < 0.05) after 9 months (Fig. 3). 
 
Amyloid pathology 
Staging of amyloid pathology development in the rat brain was assessed following the 
treatment with high STZ-icv dose (3 mg/kg) in comparison to age-matched controls. Aβ1-42 
immunoreactivity was first seen 3 months following the STZ-icv treatment in the form of 
intraneuronal Aβ1-42 accumulation in the parietal cortex (Fig. 4B, C). Extracellular Aβ1-42 
immunoreactivity in the form of aggregates that resembled human primitive plaques was 
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found in places in the neocortex and hippocampus 6 months following the STZ-icv treatment 
(Fig. 4E, H). These Aβ1-42-positive plaque-like formations were found in higher number and 
concentrated in the external capsule 9 months following STZ-icv treatment (Fig. 4F, I and J). 
No plaque-like Aβ1-42 immunoreactivity has been found in the control animals at any of the 
time-points while intraneuronal Aβ1-42 immunoreactivity of low intensity was seen in only few 
cortical neurons of control rats only 9 months after icv treatment (data not shown) probably 
indicating some age-related Aβ1-42 accumulation.  
 
AT8 immunohistochemistry 
Staging of tau protein pathology development in the rat brain was explored following the 
treatment with high STZ-icv dose (3 mg/kg) in comparison to the age-matched controls. 
Immunocytochemistry revealed positive AT8 signal in STZ-icv treated rats which indicated 
numerous early neurofibrillary changes (Fig. 5). Intracellular AT8 immunoreactivity was 
detected starting from 1 month after STZ-icv injection in the dispersed area of temporal 
cortex (Fig. 5B and C, Table 1). Interestingly, at the same time-point and at the same cortical 
location, much less intensive and more focused positive AT8 signal was also observed in the 
control animals (Fig. 5A, Table 1), Positive AT8 signal of same intensity and only at this 
location has been observed also in the controls at 3- and 6-month time-points and has 
vanished at 9-month time-point Table 1), suggesting it might be a non-specific response to 
icv injection. In contrast to the controls, the intensity of AT8 immunoreactivity in the temporal 
cortex of STZ-icv treated animals progressed with duration of the post-treatment time, and 
eventually started to appear additionally in the parietal cortex (Fig. E and F) and hippocampal 
areas CA1 and CA3 and dentate gyrus (granullar cells) where it was detected from 3 months 
after the STZ-icv treatment onward (Table 1). The signal was particularly intensive at 6 and 9 
month-time points post STZ-icv treatment (3 mg/kg) (Fig. 5H - J, L - N). Human AD brain 
tissue samples were used as a positive control (data not shown). 
 
Electron microscopy 
 
The granule cell layer of the dentate gyrus and the external granular and pyramidal 
neocortical layers were assessed for ultrastructural changes by electron microscopy. The 
ultrastructural analysis of the selected areas showed time-dependent increase in number, 
size, and electron density of lysosomes in the cytoplasm of neurons from the STZ-icv (3 
mg/kg) treated rat brains (Table 1), while very rare lysosomes of constant size and density 
were found in age-matched control animals (Fig. 6I, Table 1). In the STZ-icv treated animals 
the most abundant and largest lysosomes with compact dark granular content were found in 
the granule cell layer of the dentate gyrus 6 and 9 months after the STZ-icv treatment (Fig. 
6B – D, Table 1). Unlike the cognitive and structural changes mentioned above, some 
ultrastructural changes were seen as early as 1 week after STZ-icv treatment (Table 1). 
Irregular shape of neuronal nuclei with nuclear envelope invagination as well as the presence 
of concentrated nucleus and nucleolus with higher electron density (pyknotic nuclei) was 
found starting already from 1 week after the STZ-icv treatment (Table 1). The changes 
progressed and were prononunced 6 and 9 months following the STZ-icv treatment (3 
mg/kg) (Fig. 6F - E, Table 1). Finally, enlargement of the Golgi apparatus was observed and 
pronounced particularly 6 and 9 months after the STZ-icv treatment (3 mg/kg) (Fig. 6G, Table 
1). 
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DISCUSSION 
The STZ-icv rat model recapitulates most of sAD pathological features. Central 
administration of low STZ doses causes an insulin-resistant brain state (Agrawal et al. 2010, 
2011; Chen et al. 2013; Grünblatt et al. 2007; Lester-Coll et al. 2006; Salkovic-Petrisic et al. 
2006; Steen et al. 2005) which has been found also post-mortem in the brain of patients with 
sAD (de la Monte and Wands 2005; Frölich et al. 1999; Steen et al. 2005). Additionally, STZ-
icv treated rats demonstrate cognitive deficits, glucose hypometabolism and cholinergic 
deficit as well as oxidative stress and astrogliosis in the brain, respectively (as reviewed 
elsewhere, Salkovic-Petrisic and Hoyer 2007). Beside rats, mice (Pinton et al. 2011; 
Plaschke et al. 2010) and monkeys (Heo et al. 2011; Park et al. 2013) also generate 
reproducibly these AD-like features following the STZ-icv treatment. The STZ-icv treated rat 
represents an inducible model that circumvents generating genetically modified animals. The   
follow-up of AD-like pathology onset, development, and progression in this model could 
contribute to elucidation of sAD ethiopathogenesis as its earliest stages remain unknown in 
human. So far the STZ-icv model had been characterized up to 3 months after STZ-icv 
administration, which is insufficient to reproduce the human disease process that takes 
several decades to develop. Here we present evidence of diffuse Aβ1-42 plaque-like 
formations, accumulation of hyperphosphorylated AT8 tau protein and ultrastructural 
changes, as well as cognitive deficits, which all develop in a time- and STZ-icv dose-
dependent manner during a course of 9 months.  
Cognitive deficits have demonstrated a clear time pattern with acute decline observed 
after 1 month and a slow but progressive chronic decline seen from 3 months after STZ-icv 
treatment. It can be speculated that the intensive acute response seen after 1 month may 
reflect toxic effects of STZ (a cytotoxic compound known to induce nitrosative stress within 
the cell; Szkudelski 2001), which can be partly compensated until 3 months after the STZ-icv 
treatment (Figs 1 and 7). This tendency for compensation of acute memory impairment at 3 
months demonstrated a clear dose-dependent effect. Our results indicate that a time of 3 
months after the STZ-icv treatment seems to be a critical point at which the pathological 
processes initiated by icv injection of moderate to high STZ doses could not be compensated 
any longer, resulting in a slow and progressive memory decline. Additionally, measurement 
of cognitive deficit at 1- and 3-months demonstrated subgrouping within each STZ-icv group 
clearly indicating that cognitive pathology is completely compensated in a dose-dependent 
manner in some animals, which allows for a comparison of these early stages in STZ-icv 
model to mild cognitive impairment (MCI) in humans in which roughly 35% of affected 
patients progress to AD (Mitchell 2009). Our results are in line with the previous findings 
showing the individual susceptibility to streptozotocin as a characteristic feature of 
streptozotocin treatment in rats (Blokland and Jolles 1993; Prickaerts et al. 2000). 
Decompensation manifested as a late progression of cognitive decline in this model may 
appear as a consequence of a self-propagating destructive process in the brain which, due to 
a selective toxicity of STZ to insulin-producing and IR-expressing cells (Giorgino et al. 1992; 
Kadowaki et al. 1984; Szkudelski 2001) develops chronic insulin-resistant state with 
decreased glucose and energy metabolism (Salkovic-Petrisic et al. 2009). This may further 
lead to a dysfunction of the particular neuronal cells with dysregulation of insulin receptor 
signaling pathways which results in pathological accumulation of hyperphosphorylated tau 
protein and Aβ1-42 and is manifested as memory decline. It seems most likely that this late, 
slowly developing, progressive memory decline is the one which better mimics the situation 
in sAD. Detection of 3 to 6-month period as a critical point after the STZ treatment has been 
seen in our previous research on this model also at the level of insulin degrading enzyme 
and glycogen synthase kinase-3β protein expression in the brain (Osmanovic-Barilar et al. 
2014).  
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It is thus not surprising that the first morphological signs of amyloid pathology in our 
experiments appeared 3 months after the treatment with 3 mg/kg STZ-icv dose as 
intraneuronal Aβ1-42 accumulation (Fig. 7). Our results show that it takes 6 months after the 
STZ-icv injection for the development of extracellular diffuse plaque-like Aβ1-42 aggregates in 
rat brain (Fig. 7). Six months is also the approximate time needed for development of 
plaques in single-gene transgenic mice AD models that exhibit amyloid plaque pathology 
(PDAPP, APP23; McGowan et al. 2006). Six months represent approximatively 25% of a rat 
lifespan which, translated to humans, corresponds approximately to the development of 
clinical AD symptoms. To the best of our knowledge, this is the first morphological evidence 
of generation of diffuse plaque-like accumulation of Aβ1-42 in the brain of non-transgenic 
rodents. Positive (non-aggregated) Aβ1-42 signal in other studies was detected before 3 
months but after the treatment with STZ-icv doses 13x higher (40 mg/kg; Shingo et al. 2012, 
2013), which makes comparison with our data difficult.  
Considering the fact that STZ induces nitroso-oxidative stress, the hypothesis that, by 
acting as a reactive oxygen scavenger, increased Aβ response actually limits the oxidative 
damage (Smith et al. 2002), fits well to the recent finding of increased Aβ1-42 ELISA 
immunoreactivity detected in homogenates of rat hippocampus 5 weeks after STZ-icv 
administration which has caused severe mitochondrial abnormalities in the brain (Correia et 
al. 2013). Looking from this perspective, our results are complementary to the previously 
published data (Correia et al. 2013, Shingo et al. 2012). Namely, intracellular Aβ1-42 
accumulation in the rat brain as early as few weeks after the STZ-icv administration might be 
generated as the acute compensatory effect whose detection could be related to its intensity 
(depending on a STZ-icv dose), the method and Aβ1-42 antibody used. Our experiments have 
shown that it takes much longer time after the STZ-icv administration for a development of a 
specific AD-like extracellular Aβ1-42 accumulation. The time-course of onset and progression 
of CAA followed up to 9 months after the STZ-icv administration supports this finding 
(Salkovic-Petrisic et al. 2011). While the staging of AD by Braak and Braak (1997) is based 
on neuropathological criteria only, more recent additional studies suggest cerebral vascular 
lesions (Jellinger 2013) and CAA (Thal et al. 2002a) as of importance in the pathology of AD. 
While small vascular lesions do not seem to influence rates of cognitive decline in AD (Lee et 
al. 2000), clinicopathological studies by Grober and coworkers (Grober et al. 1999) led to the 
conclusion that both memory and mental status performance correlate with a modified Braak 
staging procedure.  
Intracellular Aβ may be a product of either an intracellular synthesis, internalization 
from an extracellular site or perhaps a combination of both (Nixon 2007). Ineffective cellular 
degradation mechanisms may culminate in the progressive accumulation of aberrant protein 
aggregates and lysosomal burden in the AD brain (Cole et al. 1989; Haass et al. 2012). 
Alterations of the neuronal endosomal-lysosomal system in AD have been found to precede 
degenerative changes, appearing at the earliest stage as lysosomal accumulation and at 
more advanced AD stages as lysosomal filling with abnormally large aggregates (Cataldo et 
al. 1994; Pimplikar et al. 2010). In line with these data on human sAD lysosomal pathology, 
the ultrastructural changes presented here indicate increment in number, size, and density of 
lysosomes in the hippocampus and neocortex of STZ-icv treated rats. Observed 
ultrastructural changes correlate with and may be speculate to reflect gradual accumulation 
of positive Aβ1-42 immunoreactivity in STZ-icv rats starting first intracellularly and then 
spreading extracellularly. This agrees with the recent evidence that Aβ may actually begin to 
accumulate intracellularly in lysosomes (Agholme et al. 2012; Tam and Pasternak 2012). In 
addition to increased lysosome numbers (Lopez et al. 2004), research in transgenic AD mice 
models also indicated that intracellular accumulation of Aβ1-42 in the endosomal/lysosomal 
system appears either before or accompanying cognitive impairment, but well before the 
appearance of amyloid plaques (Knobloch et al. 2007; Wirths et al. 2001).  
Hyperphosphorylation of tau protein is one of the most important AD hallmarks. We 
have detected increased AT8 immunoreactivity (tau protein phosphorylated at 
Ser202/Thr205 sites) in the parietal and temporal cortical regions as well as throughout the 
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hippocampus of STZ-icv treated (3 mg/kg) rats in the form of early neurofibrillary changes. 
As for Aβ1-42, AT8 immunoreactivity increased in a time-dependent manner, appearing first in 
neocortical regions 1 month after STZ-icv treatment and spreading to the hippocampal areas 
(Table 1). To the best of our knowledge, this is the first in situ evidence of increased AT8 
accumulation in STZ-icv rat model of sAD. Immunoblotting analysis has shown that 15 days 
after the STZ-icv treatment the expression of phospho (Ser199/202) tau protein is increased 
in rat neocortex and basal ganglia while no changes can be observed in the hippocampal 
region (Santos et al. 2012). Clinical studies indicate that tau protein is modified at the site 
recognized by antibody AT8 much earlier than the appearance of aggregated (fibrillar) tau, 
suggesting that phosphorylation at the AT8 site represents an earlier change than tau 
aggregation (pretangle stage) (Braak et al. 1994; Delacourte et al. 1999). These findings 
correlate well with our results of increased AT8 immunoreactivity but a lack of neurofibrillary 
tangles. Correlation of tau phosphorylation (recognized by AT8 antibody) in regions like CA3 
with regression of synaptic components and memory deficits in AD patients (Spruston 2008), 
supports our findings of cognitive deficits in parallel with AT8 immunoreactivity from 1 month 
post STZ-icv treatment. Indeed improved staging procedures based on neurofibrillary 
pathology (Alafuzoff et al. 2008; Braak et al. 2006) correlates well with the severity of 
cognitive impairment (Nelson et al. 2012). Accumulation of neuropathology (tangle counts in 
all human brain regions) appears to correlate with global cognitive decline as patients 
progress from MCI to AD (Sabbagh et al. 2010). This is underlined by experimental studies in 
a transgenic mice AD model showing that Aβ accelerates the spatiotemporal progression of 
tau pathology with augmentation of tau amyloidosis (Hurtado et al. 2010).  
 
In summary, the results presented here provide compelling evidence of the post-
treatment time- and dose-dependent development of cognitive deficits, structural and 
ultrastructural changes, as well as diffuse Aβ1-42 plaque-like formations and early 
hyperphosphorylated tau protein-related neurofibrillary changes in the STZ-icv rat model 9 
months after treatment. This study provides a comprehensive staging scheme of cognitive 
decline and neuropathogenesis in a non-transgenic rat model generated by induction of an 
insulin-resistant brain state, which eventually leads to development of AD-like 
neuropathological changes. In line with the growing body of evidence suggesting that there 
may be different endophenotypes of sporadic AD (e.g. APOE4-negative individuals or pro-
inflammatory phenotype /Borroni et al. 2006/), STZ-icv model might be considered as sAD 
endophenotype associated with insulin-resistant brain state. While respecting all limitations 
that animal models designed to mimic a human disease carry with them, it cannot be ignored 
that alterations found in STZ-icv rat model at multiple levels (cognitive, neurochemical, 
structural and ultrastructural) correlate well with one another and converge to model the sAD 
condition. Validation of STZ-icv model as a representative sAD model by taking into account 
the presenting staging scheme may contribute to more successful data translation from non-
clinical research based on this model to clinical AD trials.  
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FIGURE LEGENDS: 
 
Table 1 Summary of semiquantitative assessment / staging of the neuropathological 
and ultrastructural  findings in the STZ-icv rat model 
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Fig. 1 Nine-month follow-up of cognitive deficits in STZ-icv rat model measured in 
Passive Avoidance test. Streptozotocin (STZ) -treated and age-matched control (CTRL) 
rats were subjected to Passive Avoidance test in which latency time (s) to entering the dark 
compartment was recorded on the third testing day. Cognitive deficits manifested as lower 
latency time in comparison to the age-matched control were determined for three STZ dose 
regimens (0.3, 1 and 3 mg/kg) at 5 time-points after the treatment (1 week, and 1, 3, 6, and 9 
months). Each point represents mean ± SD of the particular group (N = 8-10). Data were 
analyzed by Kruskal-Wallis ANOVA followed by Mann-Whitney U test: *p < 0.05 vs 
respective CTRL group at each time-point; #p < 0.05 vs STZ 0.03 mg/kg group at each time-
point  
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Fig. 2 Staging of fibre loss in the rat corpus callosum following streptozotocin 
treatment (Bielschowsky silver staining). Quantitative analysis of thickness of the corpus 
callosum from the streptozotocin (STZ)-treated (0.3, 1, and 3 mg/kg) and age-matched 
control (CTRL) rats collected 1 week, and 1, 3, 6, and 9 months following the icv treatment is 
presented as a time-curve with statistically significant changes presented additionally as bars 
(mean ± SD), *p < 0.05 by Kruskal-Wallis and Mann-Whitney U test. Since the significant 
difference between the groups by Kruskal-Wallis test was detected only at 9-month time 
point only, respective (representative) microphotographs of the brain from the STZ (0.3, 1, 
and 3 mg/kg) and age-matched CTRL rats collected 9 months following the icv treatment are 
presented only. White arrows on microphotographs point to the corpus callosum. Images 
were taken at matching coronal level. Scale bar = 500 µm 
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Fig. 3 Staging of the cortical loss following streptozotocin treatment in rats (Nissl 
staining). Quantitative analysis of thickness of the parietal cortex from the streptozotocin 
(STZ)-treated (0.3, 1, and 3 mg/kg) and age-matched control (CTRL) rats collected 1 week, 1 
month, 3, 6 and 9 months following the icv treatment is presented as a time-curve with 
statistically significant changes presented additionally as bars (mean ± SD), *p < 0.05 by 
Kruskal-Wallis and Mann-Whitney U test. The significant difference between the groups by 
Kruskal Wallis test was detected at 1, 3 and 9-month time points and respective 
(representative) microphotographs of the brain from the STZ-icv treated (0.3, 1, and 3 mg/kg) 
and age-matched control rats are presented as well. Black arrows on microphotographs point 
to the parietal cortex. Images were taken at matching coronal level. Scale bar = 500 µm 
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Fig. 4 Aβ1-42 accumulation of in the brain of STZ-icv treated rats, visualized by Aβ1-42 
immunohistochemistry. The figure shows representative microphotographs of the brain 
from the streptozotocin (STZ, 3 mg/kg)-treated rats and age-matched controls (CTRL) (A, D, 
G) obtained 3, 6 and 9 months following the treatment, respectively. Three months following 
the STZ treatment positive signal revealed only intracellular Aβ1-42 accumulation in the 
parietal cortex (B, C) while starting from the 6-month time-point (E, F) up to 9 months (H, I), 
positive signals of both intra- and extracellular primitive plaque-like Aβ1-42 accumulation were 
found predominantly in the parietal cortex (F -small insert) and to a lesser extent in the 
hippocampus. Scale bar = 100 µm, except for Fig. 4I and a small insert at Fig. 4F: scale bar 
= 10 µm 
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Fig. 5 Immunoreactivity of hyperphosphorylated tau protein in the brain of STZ-icv 
treated rats, visualized by AT8 immunohistochemistry. The figure shows representative 
microphotographs of the brain from the streptozotocin (STZ, 3 mg/kg)-treated rats (B, C, E, 
F, H – J, L – N) and age-matched controls (CTRL) (A, D, G, K) obtained 1 month, 3, 6 and 9 
months following the treatment. Representative microphotographs present intracellular AT8 
immunoreactivity seen in the hippocampal CA3 region (H - J, 6 months), granular cell layer 
of the dentate gyrus (N, 9 months) and in the parietal cortex (B and C, 1 month; E and F, 3 
months; L and M, 9 months). Scale bar = 50 µm, except for Fig. 5H: scale bar = 200 µm 
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Fig. 6 Ultrastructural changes in the brain of STZ-icv treated rats. The figure shows 
representative microphotographs of the neurons in (A – D) the granule cell layer of the 
dentate gyrus (DG) and (E – H) the pyramidal layers (CTX) in the streptozotocin  (STZ, 3 
mg/kg)-treated rats obtained 3, 6 and 9 months following the treatment. Representative 
microphotograph of control (CTRL) rats (6-month time-point) is presented for comparison (I). 
The photomicrographs show the lysosomes and their dark granular content marked with 
white arrows (A – E), and pyknotic nucleus (F), enlargement of the Golgi apparatus with 
swollen terminal cisternae (G) and nuclear envelope invaginations (H) marked with black 
arrows. Scale bar is marked at each microphotograph 
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Fig. 7 Staging of cognitive deficits and underlying neuropathological and 
ultrastructural changes in the brain of a STZ-icv rat model. The figure presents the 
correlation of staging of cognitive deficits and structural/ultrastructural changes in a 
streptozotocin (STZ)-induced rat model of sporadic Alzheimer's disease (sAD). Data present 
findings obtained in animals treated intracerebroventricularly (icv) with 3 mg/kg STZ dose. 
Ultrastructural changes (pyknotic nuclei, lysosomal changes) of mild intensity appeared 
before (starting from 1 week after the STZ treatment) the structural changes and cognitive 
deficits in this experimental design (both starting from 1 month after the STZ treatment). The 
order of appearance in the 9-month post STZ-treatment period (from the earliest to the latest 
event) was: ultrastructural changes < early neurofybrillary changes (AT8) and acute cognitive 
decline < intracellular amyloid β1-42 accumulation < extracellular plaque-like Aβ1-42 
accumulation and chronic progressive cognitive decline. While ultrastructural and structural 
changes were both slowly progressing in the course of time, the cognitive deficits followed a 
triphasic pattern; (I) acute decline, (II) partial amelioration of cognitive decline, (III) chronic 
progressive cognitive decline. Three months after the STZ treatment seemed to be a critical 
point at which the pathological processes initiated by high STZ dose (3 mg/kg) could not be 
compensated any longer, resulting in a slow and progressive memory decline which 
correlated well with the first appearance of pathological Aβ accumulation. Not only that 
pathological Aβ accumulation appeared later than tau protein-related neurofibrillary changes 
and ultrastructural abnormalities, based on the arbitrary unit scale (0-5), it was also of the 
lower intensity 9 months after the STZ treatment compared to neurofibrillary and 
ultrastructural changes (≤ 3 vs ≤ 5). Considering the structural and ultrastructural changes 
observed in this 9-month follow-up, it seems most likely that the late, slowly developing, 
progressive memory decline in the STZ-icv rat model is the one which better mimics the 
situation in sAD 
